ÂÜÀòÂÒÂ×

Dr. Saponjic is the Vice President Clinical Operations at Immunovant. Dr. Saponjic has more than 25 years of drug development experience in the areas of global operations, project management, clinical operations, clinical systems and CRO Management. Prior to Immunovant, he was the Vice President, Clinical Operations at Respivant responsible for development of RVT1601 for the treatment of Idiopathic Pulmonary Fibrosis patients, clinical department management, and member of Executive Leadership Team. Prior to Respivant, he was Vice President Global Development Operations at Greenwich Biosciences, responsible for development governance structures, clinical operations, portfolio pipeline process, and supporting the NDA submission and FDA approval for Epidiolex®. Prior to Greenwich, he held senior management positions at biotech, CRO, and Genomics companies including: AirPharma, Alkensa Clingenix, Monitorforhire.com, Patara Pharma, Quintiles, and Synteract. He earned a BA in Psychology at Texas Tech University, MS and PhD in Neuroscience at Texas Christian University, and an MBA from Baker University.